Blue Jet Healthcare
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Blue Jet Healthcare is currently navigating a recovery phase, bolstered by a robust order book and strategic investments, particularly the INR 10 billion expansion in Vizag aimed at diversifying its product portfolio. Management's focus on a CDMO-centric model and vertical integration is expected to enhance revenue growth, particularly in the contrast media segment, which is projected to achieve double-digit growth in FY27. However, the company faces short-term challenges from raw material price volatility and execution risks associated with new product launches. Vista's financial outlook reflects a cautious optimism, with revenue growth recovering and margins expected to remain stable, aligning with the company's strategic initiatives. The favorable macro environment for Indian equities, coupled with the industry's expansion driven by global supply chain shifts, supports Blue Jet's growth trajectory. Over the next 12-24 months, key opportunities include the successful commercialization of new facilities and product lines, while watchpoints include potential raw material inflation and execution risks in scaling operations
Why We Like This Stock
- Strategic investment in the Vizag facility is expected to diversify product offerings and enhance manufacturing capacity
- Management anticipates double-digit growth in the contrast media segment, driven by stable demand and new product launches
- The company's focus on a CDMO-centric model positions it well to capitalize on increasing outsourcing trends in the pharma sector
Things To Watch Out For
- Short-term headwinds from raw material price volatility may impact margins and earnings estimates
- Execution risks related to new product ramp-up and higher customer concentration could pose challenges to growth
- Potential volatility in order patterns and operating costs amidst fluctuating sales volumes may affect financial stability
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 712 | 1,030 | 947 | 1,028 | 1,153 |
| Profit Before Tax (Cr.) | 230 | 398 | 333 | 380 | 419 |
| PBT Margin | 32.3% | 38.6% | 3516.4% | 37.0% | 36.3% |
| Net Profit (Cr.) | 173 | 303 | 251 | 289 | 318 |
| Earnings Per Share | 10.0 | 17.5 | 14.5 | 16.7 | 18.4 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| ICICI Securities | ▲ Buy | 680 | 04-Aug-2026 |
| JPMorgan | ▼ Reduce | 370 | 26-May-2026 |
| Kotak Securities | ► Add | 505 | 26-May-2026 |
| Motilal Oswal | ▲ Buy | 710 | 05-Aug-2026 |
Company Overview
Show Company Profile
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related salts. It has operations in India, Norway, France, the United States, Italy, Sweden, and internationally. Blue Jet Healthcare Limited was incorporated in 1968 and is headquartered in Thane, India.